Jury awards $5 million in HRT-breast cancer case 
By:
Sylvia Hsieh
Published: September 21, 2012
Tags: breast cancer, drug litigation, hormone replacement therapy, HRT, HRT litigation, Pfizer, Prempro, product liability, Provera, Upjohn, Wyeth
A woman who developed breast cancer after taking combination hormone therapy drugs including Premarin, Provera and Prempro for 15 years won a $5 million award against drug companies Wyeth and Upjohn this month.
Prempro expert could testify regarding short-term use
Published: July 30, 2012
Tags: breast cancer, Daubert, expert witness, hormone replacement therapy, Prempro, Wyeth
Product liability plaintiffs should have been permitted to introduce expert testimony linking the short-term use of Prempro to a risk of breast cancer, the 8th Circuit has ruled in reversing a summary judgment.
Prempro payouts to approach $1.2B, Pfizer projects
Published: June 27, 2012
Tags: drug litigation, hormone replacement therapy, Pfizer, Premarin, Prempro, Provera
Drug maker Pfizer has set aside an additional $330 million to cover its liability for hormone-replacement therapy drugs like Prempro, Premarin and Provera, indicating in a regulatory filing that total payouts for those claims will probably approach $1.2 billion.
Woman wins $4 million in Prempro breast cancer trial
By:
Sylvia Hsieh
Published: April 27, 2012
Tags: breast cancer, drug litigation, hormone replacement therapy, HRT litigation, Pfizer, Prempro, Wyeth
A 65-year-old elementary school principal has won a $4 million verdict in Connecticut federal court against the maker of the menopause drug Prempro for causing her breast cancer.
Prempro plaintiff can’t show causation, District Court rules
Published: March 13, 2012
Tags: breast cancer, causation, failure to warn, hormone replacement therapy, Premarin, Prempro, product liability, Provera, Upjohn, Wyeth
A product liability plaintiff could not show that the alleged failure of pharmaceutical companies to warn about the dangers of their hormone therapy drugs was the proximate cause of her breast cancer, a U.S. District Court in South Carolina has ruled in granting summary judgment.
Pfizer settles nearly half of Prempro claims, adds to reserve
Published: December 29, 2011
Tags: hormone replacement therapy, Prempro, product liability, SEC, Securities and Exchange Commission
Drug maker Pfizer and its affiliates have settled nearly half of the product liability claims involving the hormone-replacement therapy drugs Prempro, Premarin and Provera, according to a regulatory filing.
Plaintiff’s expert can’t testify in Prempro case
Published: July 25, 2011
Tags: breast cancer, expert witness, hormone replacement therapy, Premarin, Prempro, product liability, Provera
A treating physician could not testify as an expert in a product liability lawsuit alleging that the plaintiff’s breast cancer was caused by her ingestion of hormone replacement therapy drugs, a U.S. District Court in West Virginia has ruled.
Small firm turns the tide on Prempro litigation
By:
Sylvia Hsieh
Published: January 18, 2011
Tags: breast cancer, hormone replacement therapy, hormone replacement therapy litigation, HRT litigation, Prempro, Wyeth, Wyeth Pharmaceuticals
In the ongoing mass tort over the hormone replacement therapy drug Prempro, two small firms recently teamed up to break the defense winning streak in the trials.
Drug litigation in review 2010
By:
Tony Ogden
Published: January 4, 2011
Tags: Accutane, Allergan, antidepressant, Avandia, AztraZeneca, Botox, Botox litigation, Department of Justice, DOJ, epilepsy, failure to warn, GlaxoSmithKline, heart attack, hormone replacement therapy, hormone replacement therapy litigation, Johnson & Johnson, Levaquin, Neurontin, Paxil, Pfizer, Premarin, Prempro, Provera, Roche, Seroquel, Wyeth
Much like 2009, 2010 was a busy year for prescription drug suits.
Hormone drug plaintiffs must show reliance
By:
Pat Murphy
Published: January 3, 2011
Tags: consumer protection, deceptive trade practices, hormone replacement therapy, product liability, reliance, Wyeth
Consumers must show detrimental reliance in order to hold a drug manufacturer liable for misleading statements in its marketing of hormone replacement therapy drugs, West Virginia’s highest court has ruled.
